Researchers from the St. Marianna University School of Medicine in Kawasaki, Japan recently presented findings at the 2021 ESMO Congress on Gastrointestinal Cancer, indicating that "genomic pathways and bacterial genera in the pre-treatment gut microbiome of patients with advanced gastric cancer...were significantly associated with survival times following treatment with nivolumab." Further, findings from the translational study determined that genomic pathways in the gut were associated with survival time following nivolumab in patients with advanced gastric cancer.
To read more about this study, click here.
Sources mentioned:
Sunakawa Y, Matoba R, Inoue E, et al. Genomic pathway of gut microbiome to predict efficacy of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08). Journal of Clinical Oncology 2021;39(3_suppl):161-161.
O13 – Sunakawa Y, Matoba R, Inoue E, et al. Gut Microbiome to Predict Survival Time in Advanced Gastric Cancer Treated With Nivolumab: the DELIVER Trial (JACCRO GC-08). ESMO World Congress on Gastrointestinal Cancer 2021 (30 June - 3 July).
No comments:
Post a Comment